Ryvu Therapeutics

Partnership since August 2017

Ryvu

In August 2017, LLS TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome."

Ryvu Therapeutics is a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology. RVU120 is a highly selective first-in-class CDK8/CDK19 inhibitor that was discovered with the Ryvu Therapeutics discovery engine platform. CDK8 plays a unique and critical role in gene regulation and is implicated in the development of numerous hematological malignancies and solid tumors.

Ryvu is currently enrolling several Phase 2 clinical trials:

  • RVU120 as monotherapy in genetically defined cohorts of patients with relapsed/refractory AML and high-risk myelodysplastic syndromes (RIVER-52, NCT06268574)
  • RVU120 in combination with venetoclax for patients with relapsed/ refractory AML (RIVER-81, NCT06191263)
  • RVU120 as monotherapy for patients with low-risk myelodysplastic syndromes (REMARK, NCT06243458)
  • RVU120 as monotherapy and in combination with ruxolitinib for patients with myelofibrosis (POTAMI-61, NCT06397313)

For more information about Ryvu, visit ryvu.com.

Recent News

  • September 19, 2024 - announced that the first patient has been dosed in the REMARK study, a Phase II clinical trial investigating RVU120 as a monotherapy for the treatment of patients with LR-MDS. 

  • January 31, 2024 - announced that the first patient has been dosed with the study drugs in a Phase 2 clinical trial investigating RVU120 in combination with venetoclax for the treatment of patients with relapsed/refractory acute myeloid leukemia (r/r AML) – the RIVER-81 study.

  • March 15, 2023 - named the Warsaw Stock Exchange Company of the Year in a competition organized by the largest business daily in Poland - Puls Biznesu.

  • December 22, 2022 – announced the completion of its public offering of Series J common shares. As a result, Ryvu has obtained gross proceeds of PLN 250.3 million ($57M USD) from institutional and individual investors as well as BioNTech and The Leukemia & Lymphoma Society (LLS).

  • December 11, 2022 – announced new data demonstrating clinical and preclinical activity of its selective CDK8/19 inhibitor RVU120 at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held on December 10 –13, 2022, in New Orleans, Louisiana.

  • May 12, 2022 - announced that the data from the Phase 1b dose-escalation study of RVU120 (SEL120) in patients with AML or high-risk myelodysplastic syndromes (HR-MDS) will be presented at the Annual EHA 2022 Hybrid Congress, June 9-17 in Vienna, Austria.